Buscar
Bioventus Inc
BVSAñadir a la lista de seguimiento
13.170USD
-0.010-0.08%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
892.24MCap. mercado
30.81P/E TTM
Más Datos de Bioventus Inc Compañía
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Información de Bioventus Inc
Símbolo de cotizaciónBVS
Nombre de la empresaBioventus Inc
Fecha de salida a bolsaFeb 11, 2021
Director ejecutivoClaypoole (Robert E)
Número de empleados930
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 11
Dirección4721 Emperor Boulevard, Suite 100
CiudadDURHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27703
Teléfono19194746700
Sitio Webhttps://www.bioventus.com/
Símbolo de cotizaciónBVS
Fecha de salida a bolsaFeb 11, 2021
Director ejecutivoClaypoole (Robert E)
Ejecutivos de Bioventus Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Katrina Church, J.D.
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
--
--
Mr. William A. (Bill) Hawkins, III
Mr. William A. (Bill) Hawkins, III
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
--
--
Marty Sutter ,
Marty Sutter ,
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bioventus Inc?
Los cinco principales accionistas de Bioventus Inc son: Ms. Susan M. Stalnecker
¿Cuántas instituciones poseen acciones de Bioventus Inc (BVS)?
A fecha de 2026Q1, 339 instituciones poseen acciones de Bioventus Inc, con un valor de mercado combinado de aproximadamente 52.51M, lo que representa el 77.51% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -10203484.00.
¿Cuál es la mayor fuente de ganancias de Bioventus Inc?
El 2026Q1, el segmento empresarial Pain Treatments generó la ganancia más alta para Bioventus Inc, ascendiendo a 279.06M y representando el 49.12% de la ganancia total.